Selecta Biosciences, Inc. (NASDAQ:SELB) reported earnings of ($0.85) per share beating Walls Streets expectations.

ME Staff
-
0

Selecta Biosciences, Inc. (NASDAQ:SELB) reported Q2 2017 earnings this N/A, coming in at ($0.85) per share, beating Wall Street’s estimates of ($0.86) per Share. Revenue for the quarter came in at $0.03 million missing the streets estimates

Analyst Coverage For Selecta Biosciences, Inc. (NASDAQ:SELB)
These are 3 Buy Ratings .
The current consensus rating for Selecta Biosciences, Inc. (NASDAQ:SELB) is Buy (Score: 3.00) with a consensus target price of $28.33 , a potential (80.81% upside)

Recent Insider Trading for Selecta Biosciences, Inc. (NASDAQ:SELB)

  • On 7/3/2017 Lloyd P Johnston, COO, sold 5,959 with an average share price of $19.10 per share and the total transaction amounting to $113,816.90.
  • On 6/30/2017 David Siewers, CFO, sold 7,420 with an average share price of $20.00 per share and the total transaction amounting to $148,400.00.
  • On 6/29/2017 David Siewers, CFO, sold 9,652 with an average share price of $20.00 per share and the total transaction amounting to $193,040.00.
  • On 6/27/2017 Peter Keller, Insider, sold 4,595 with an average share price of $19.30 per share and the total transaction amounting to $88,683.50.
  • On 6/27/2017 Timothy A Springer, Director, bought 338,791 with an average share price of $17.71 per share and the total transaction amounting to $5,999,988.61.
  • On 6/26/2017 David Siewers, CFO, sold 6,886 with an average share price of $20.00 per share and the total transaction amounting to $137,720.00.



    Recent Trading for Selecta Biosciences, Inc. (NASDAQ:SELB)
    Shares of Selecta Biosciences, Inc. closed the previous trading session at 15.67 down -1.30 -7.66% with 109,680 shares trading hands.